Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C treatment news

Show

From To
Indonesian buyers club helps people obtain generic hepatitis C treatment

A community-led buyers club in Indonesia has helped more than 100 people get generic direct-acting antiviral (DAA) drugs to treat hepatitis C and is seeing a high

Published
24 May 2017
By
Liz Highleyman
China captures 12 smugglers of Indian pharmaceuticals

Chinese police have detained 12 people for smuggling and selling Indian-made treatments for hepatitis C and cancer, authorities said Wednesday.

Published
24 May 2017
From
Xinhua
Hepatitis C virus reinfection is uncommon after being cured with DAAs

Most people on opiate substitution therapy were successfully treated for hepatitis C with an interferon-free regimen of grazoprevir/elbasvir (Zepatier), and only a small number became reinfected during

Published
19 May 2017
By
Liz Highleyman
Costs for generic hepatitis C drugs available in India would be paid back in 5 to 10 years

Use of the generic versions of directly-acting antiviral drugs that are available in India to treat hepatitis C virus infection is not only cost effective but actually saves lifetime costs for treating infected patients in that country.

Published
18 May 2017
From
Eurekalert Inf Dis
Surgeons plan to use hepatitis-infected hearts to slash wait for a transplant

As many as 1,000 such infected kidneys are thrown away each year in the United States, but new medications have made hepatitis C curable — and made it possible to consider using infected organs for transplants. That could cut down on the wait time not just for kidneys but also other organs, especially hearts.

Published
15 May 2017
From
STAT
Early Access to Medicines Scheme (EAMS) Granted to AbbVie’s Investigational Pan-genotypic Regimen for Chronic Hepatitis C in UK

The UK scheme makes glecaprevir/pibrentasvir available to people with compensated cirrhosis and prior treatment with an NS5A inhibitor (genotypes 1, 4, 5 or 6), chronic kidney disease (genotypes 2, 3, 5 or 6) or genotype 3 with previous exposure to pegylated interferon, ribavirin and/or sofosbuvir.

Published
10 May 2017
From
AbbVie press release
BC-developed hepatitis C screening test personalizes treatment for patients

Scientists in Vancouver have developed a new screening tool that reveals the genetic signature of an individual’s hepatitis C virus so that doctors can customize their treatment.

Published
10 May 2017
From
The Globe and Mail
Louisiana proposes tapping a century-old patent law to cut hepatitis C drug prices

Continuing public concerns over high-priced hepatitis C drugs are taking a new twist as Louisiana’s top health official proposes using an obscure federal patent law to get the medicines at a much lower cost. If successful, other states could reap the benefits.

Published
03 May 2017
From
Washington Post
New website launched to help prevent spread of hepatitis C

A group of researchers launched a new website Wednesday that lays out a roadmap to curb the spread of hepatitis C. HepVu is the result of a public-private partnership aimed to help the estimated 3.9 million Americans who currently have or have had hepatitis C

Published
28 April 2017
From
ModernHealthcare.com
Triple combination cures most hepatitis C patients with prior DAA treatment failure

Almost all people with genotype 1 hepatitis C who were previously unsuccessfully treated with a course of interferon-free direct-acting antiviral therapy achieved sustained response when retreated with a

Published
28 April 2017
By
Liz Highleyman
← First12345...90Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.